
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) – HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a report released on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($1.85) per share for the year, up from their previous forecast of ($2.39). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($1.80) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.90) EPS, FY2028 earnings at ($1.64) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($0.42) EPS.
A number of other research firms also recently issued reports on ZNTL. William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They set an “outperform” rating for the company. Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 30th. They issued an “equal weight” rating and a $5.00 price objective on the stock. Wedbush raised Zentalis Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $5.00 to $6.00 in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Friday, October 2nd. Finally, Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.29.
Zentalis Pharmaceuticals Stock Performance
Zentalis Pharmaceuticals stock opened at $1.70 on Thursday. Zentalis Pharmaceuticals has a one year low of $1.28 and a one year high of $6.95. The business has a fifty day moving average of $2.53 and a two-hundred day moving average of $3.38. The company has a market cap of $121.84 million, a P/E ratio of -0.89 and a beta of 1.91.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.20.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of ZNTL. CTC Alternative Strategies Ltd. purchased a new position in shares of Zentalis Pharmaceuticals during the 1st quarter worth $29,000. Spark Investment Management LLC acquired a new position in Zentalis Pharmaceuticals in the second quarter valued at $61,000. The Manufacturers Life Insurance Company purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $69,000. State of Wyoming purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $91,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth about $126,000.
Recent Zentalis Pharmaceuticals Headlines
Investors following ZNTL have been watching these headlines:
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $10 price target while substantially narrowing its projected losses for 2026–2028. For example, its FY2027 EPS forecast improved to ($1.90) from ($2.76), and its FY2028 estimate improved to ($1.64) from ($2.13). The repeated reports describe the same broad estimate revisions, rather than separate analyst actions.
- Positive Sentiment: Wedbush upgraded Zentalis’s stock rating, another potentially supportive analyst signal. Zentalis Pharmaceuticals Stock Rating Upgraded by Wedbush
- Neutral Sentiment: Morgan Stanley maintained a Hold rating, indicating it did not see enough reason to change its stance. Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.
Featured Articles
- Five stocks we like better than Zentalis Pharmaceuticals
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
